oncologyconsultingintel.blogspot.com
Cancer Competitive IntelligenceNew oncology developments in the world of pharmaceuticals and biotechnology
http://oncologyconsultingintel.blogspot.com/
New oncology developments in the world of pharmaceuticals and biotechnology
http://oncologyconsultingintel.blogspot.com/
TODAY'S RATING
>1,000,000
Date Range
HIGHEST TRAFFIC ON
Friday
LOAD TIME
0.6 seconds
PAGES IN
THIS WEBSITE
17
SSL
EXTERNAL LINKS
0
SITE IP
172.217.10.129
LOAD TIME
0.578 sec
SCORE
6.2
Cancer Competitive Intelligence | oncologyconsultingintel.blogspot.com Reviews
https://oncologyconsultingintel.blogspot.com
New oncology developments in the world of pharmaceuticals and biotechnology
oncologyconsultingintel.blogspot.com
Cancer Competitive Intelligence: Improving survival in Liver Cancer - at what cost?
http://oncologyconsultingintel.blogspot.com/2008/07/improving-survival-in-liver-cancer-at.html
New oncology developments in the world of pharmaceuticals and biotechnology. Monday, July 28, 2008. Improving survival in Liver Cancer - at what cost? No effective therapy is available for advanced hepatocellular carcinoma. In this month's New England Journal of Medicine. A randomised trial involving 602 patients with advanced hepatocellular carcinoma was reported. Sorafenib. An editorial by Dr Lewis Roberts. In the same journal noted the following:. Subscribe to: Post Comments (Atom). Follow Me on Twitt...
Cancer Competitive Intelligence: July 2008
http://oncologyconsultingintel.blogspot.com/2008_07_01_archive.html
New oncology developments in the world of pharmaceuticals and biotechnology. Monday, July 28, 2008. Improving survival in Liver Cancer - at what cost? No effective therapy is available for advanced hepatocellular carcinoma. In this month's New England Journal of Medicine. A randomised trial involving 602 patients with advanced hepatocellular carcinoma was reported. Sorafenib. An editorial by Dr Lewis Roberts. In the same journal noted the following:. Links to this post. Wednesday, July 23, 2008. It looks...
Cancer Competitive Intelligence: Using social media tools for competitive intelligence
http://oncologyconsultingintel.blogspot.com/2008/10/using-social-media-tools-for.html
New oncology developments in the world of pharmaceuticals and biotechnology. Friday, October 17, 2008. Using social media tools for competitive intelligence. The last few years have seen a rise in all sorts of web 2.0 social media tools, so much so that the choices are becoming rapidly bewildering. They range from old stalwarts such as LinkedIn,. To new kids on the block such as Twitter. Twitter also has an incorporated search function (formerly Summize. Thus allowing the user to search the whole Twitter...
Cancer Competitive Intelligence: Procrit linked to deaths in stroke patients
http://oncologyconsultingintel.blogspot.com/2008/10/procrit-linked-to-stroke-in.html
New oncology developments in the world of pharmaceuticals and biotechnology. Wednesday, October 1, 2008. Procrit linked to deaths in stroke patients. Has informed the FDA. Of preliminary safety findings from a clinical trial conducted in Germany investigating the use of Procrit. The trial was designed to determine whether the drug could help patients who have had an acute ischaemic stroke, an unapproved indication in both the EU and US. Related articles by Zemanta. Study Finds Death Risk From Anemia Drugs.
Cancer Competitive Intelligence: September 2008
http://oncologyconsultingintel.blogspot.com/2008_09_01_archive.html
New oncology developments in the world of pharmaceuticals and biotechnology. Thursday, September 11, 2008. In lieu of 9/11. There will be no blog posts today as a mark of respect. Links to this post. Tuesday, September 2, 2008. Abiraterone and prostate cancer. One drug that has been tearing up the newsfeed this year is abiraterone, a novel drug in phase II trials for prostate cancer. In February, data. Was presented at ASCO's Genito-urinary satellite meeting. Related articles by Zemanta. New England J Med.
TOTAL PAGES IN THIS WEBSITE
17
oncologycongress.showsite.ri-nova.com
Oncology Congress - A CME Conference for Practicing US Oncologists
The Sixth Annual Oncology Congress. October 15-17, 2010 San Francisco. Thank you for attending the 5th Annual Oncology Congress - we look forward to seeing you next year, October 15-17, 2010 in San Francisco. Be on the lookout for an email within the next few weeks that will provide all attending participants with access to view recorded sessions from the conference. Access the 2009 Oncology Congress Presentations Here. Stay Informed about Oncology Congress Get on Our Email List. Head and Neck Cancer.
oncologyconsult.org
Oncology Consulting & Cancer Consulting - Oncology Resource Consultants
ORC offers a comprehensive array of services to hospitals, physicians, pharmaceutical companies, law firms, and the biotechnology community. 104 South Washington Street Rockville, MD 20850 P (301) 424-6000 F (301) 424-6005.
Oncology Consultants | Houston, TX | Overcoming Cancer
Media & Events. Introduction to Cancer Treatment. A Word about Clinical Trials. Getting a Second Opinion. Head and Neck Cancer. What Are Clinical Trials? Phases of Clinical Trials. How Are Clinical Trials Conducted? Participating in Clinical Trials. The Cost of Clinical Trials. Finding Specific Clinical Trials. The Future of Clinical Trials. Side Effects of Treatment. Diagnostic and Monitoring Tests. Lung Cancer - Non-Small Cell. Lung Cancer - Small Cell. Head and Neck Cancer. Birth Control and Sexuality.
oncologyconsultantsbahamas.com
Oncology Consultants Bahamas
Providing World Class Cancer Care to the Caribbean". Our Mission and Goals. Dr DuVaughn E. Curling. Dr Andre R. Clarke. Dr Theodore Turnquest received his Doctor of Medicine degree from the University of South Florida in 1995. He completed his Internal Medicine residency at Baylor College of Medicine in Houston, Texas. Dr DuVaughn E. Curling. Designed by X-tine Media.
oncologyconsultingintel.blogspot.com
Cancer Competitive Intelligence
New oncology developments in the world of pharmaceuticals and biotechnology. Monday, August 24, 2009. Resumption after an extended hiatus. Things have been really insanely busy on the work front over the last year, necessitating some radical prioritisation and thus I have only posted on Pharma Strategy Blog. Instead of here and Oncology Market Trends. Normal service will resume shortly. Links to this post. Saturday, October 18, 2008. Increasing importance of competitive intelligence in bear markets.
oncologyconsultingnews.blogspot.com
Pharma Market Strategy
News and views from the world of pharmaceuticals and biotechnology. Monday, August 24, 2009. Resumption after an extended hiatus. Things have been really insanely busy on the work front over the last year, necessitating some radical prioritisation and thus I have only posted on Pharma Strategy Blog. Instead of here and Oncology Market Trends. Normal service will resume shortly. Monday, October 13, 2008. When tomorrow never comes. the rising cost of health care. The National Coalition on Health Care.
Oncology Convergence, Inc. (OCI)
Skip to main content. Call us : 1-877-754-7799. OCI combines clinical and financial experience to assist and guide oncology practices to maximize profits without sacrificing patient care, time or compliance. We help you work smarter. The OCI team focuses on oncology reimbursement, management, and technology. Oncology Convergence, Inc. (OCI) has one of the most specialized teams in the industry. December 27, 2016. By Jim Musslewhite, President, Oncology Convergence, []. Bad Debt, the Profit Killer.
Oncology, Corpus Christi Texas, Dr. Lalitha Janaki
Helping our patients to achieve the highest levels of wellness. Recognizing the need for professional, caring cancer treatment closer to patient’s homes, Dr. Ayman Ghraowi and Dr. Lalitha Janaki established the Christus Spohn Cancer Center Calallen network of clinics in 1996. Christus Spohn Cancer Center Calallen is the only cancer specialty group with offices in Corpus Christi, Aransas Pass, Alice, Beeville, Calallen, Kingsville and Rockport. Cancer and blood disorder consultation. Bull; TMA Delegate.
Oncology Case of the Week (COW)
Oncology Case of the Week (COW). Beings medicine: Chinese medicine to first-class brand enterprise forward - beings medicine - pharmaceutical industries. December 11, 2009, and the people listed on medicine in the Shenzhen Stock Exchange, becoming the sixth listed companies in Dongguan, Dongguan, achieved nearly 11 years IPO breakthrough. Britain is expected to Traditional Chinese Medicine Act enacted in 2011 - Medicine, United Kingdom - Pharmaceutical Industry. Look no further than the Southwest College...
Oncology Education
Sunday, 27 May 2012. Getting Better: 200 Years of Medicine. Well, this web space is becoming another area to share more and more videos from other sources.As a CPD space, that is OK in a way,if those videos are from legitimate sources, but not having any original content is not very good for a web space dealing with professional development . From next month onwards, we are trying to publish a column on Oncology research- A synopses of all the main oncology journals and original articles that month.
